Market News / Story
GenSight Biologics Reports Cash Position as of September 30, 2026
BusinessWire ·
BusinessWire reports: Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2026. Cash Position and Early Access Programs as of September 30, 2026 GenSight Biologics’ cash and cash equivalents amounted to €0.7 million as of September 30,…